Press release
PEGylated Protein Therapeutics Market Share, Growth, Statistics, Development, Trend, Demand, End User Analysis
PEGylated Protein Therapeutics Market
๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐๐ฒ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ :
The report provides an extensive competitive analysis and profiles of the key market players such as Amgen Inc., AstraZeneca PLC, Biogen, Inc., F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Horizon Pharma plc., Leadiant Biosciences S.p.A., Merck & Co., Inc. (Schering-Plough Corporation), Pfizer Inc., Shire plc (Baxalta), and UCB S.A.
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/request-sample/3726
๐๐๐ ๐ ๐๐๐๐๐๐๐ ๐๐ ๐๐๐ ๐๐๐๐๐
โข North America occupied nearly two-thirds share of the global PEGylated protein therapeutics market in 2017
โข The cancer segment is anticipated to grow with the highest CAGR throughout the forecast period.
โข Europe is anticipated to occupy one-fifth market share of the global PEGylated protein therapeutics market by 2025.
โข Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.
๐ ๐จ๐ซ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ง๐ช๐ฎ๐ข๐ซ๐ฒ https://www.alliedmarketresearch.com/purchase-enquiry/3726
PEGylation is a process of addition of active polyethylene glycol (PEG) to different forms of therapeutic proteins for chemical modification. These chemically modified therapeutic proteins are called PEGylated protein therapeutics. The chemical modification due to PEGylation results in various advantages, such as an extended half-life of a drug along with low toxicity and increased proteolytic protection, over the non-modified protein therapeutics. PEGylated protein therapeutics are used in multiple conditions such as cancer, hemophilia, rheumatoid arthritis, ankylosing spondylitis, Crohns disease, and others.
The factors that drive the growth of the global PEGylated protein therapeutics market are increase in prevalence of chronic diseases, advantages offered by PEGylation, and strong presence of pipe line drugs are. However, high cost related to drug development and launch of generics during the forecast period are expected to impede the market growth. In addition, high market potential in the untapped emerging economies and increase in adoption of PEGylated protein therapeutics are expected to provide many opportunities during the forecast period.
By product type, the colony stimulating factor segment accounted for nearly half share of the global occupational medicine market in 2017. Furthermore, the cancer segment is anticipated to grow at the highest rate of 7.4% during the forecast period.
๐๐ฒ๐ ๐๐ฒ๐๐ฎ๐ถ๐น๐ฒ๐ฑ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/PEGylated-proteins-market
๐๐ญ๐ก๐๐ซ ๐๐ซ๐๐ง๐๐ข๐ง๐ ๐๐๐ฉ๐จ๐ซ๐ญ๐ฌ:
Digital Radiology/Radiography Market https://www.alliedmarketresearch.com/digital-radiology-market
Tattoo Removal Market https://www.alliedmarketresearch.com/tattoo-removal-market
Contact:
David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release PEGylated Protein Therapeutics Market Share, Growth, Statistics, Development, Trend, Demand, End User Analysis here
News-ID: 2582054 • Views: โฆ
More Releases from Allied Analytics LLP
Solar Energy Storage Market to Reach $20.9 Billion by 2031 Driven by Renewable E โฆ
According to a new report published by Allied Market Research, the solar energy storage market size was valued at $9.8 billion in 2021 and is estimated to reach $20.9 billion by 2031, growing at a CAGR of 7.9% from 2022 to 2031. The increasing deployment of renewable energy systems, rising demand for reliable power storage, and supportive government policies promoting clean energy are major factors driving the growth of theโฆ
Sodium Ion Battery Market to Reach $1.2 Billion by 2031 Driven by Energy Storage โฆ
According to a new report published by Allied Market Research, the sodium ion battery market size was valued at $0.3 billion in 2021 and is estimated to reach $1.2 billion by 2031, growing at a CAGR of 15.9% from 2022 to 2031. The rapid adoption of advanced energy storage technologies, increasing demand for cost-effective battery solutions, and the global transition toward sustainable energy systems are significantly contributing to the expansionโฆ
Redox Flow Battery Market to Reach $403 Million by 2026 Amid Rising Renewable En โฆ
According to a new report published by Allied Market Research, the global redox flow battery market size was valued at $130.4 million in 2018 and is projected to reach $403.0 million by 2026, growing at a CAGR of 15.2% from 2019 to 2026. The rapid growth of renewable energy deployment, rising demand for large-scale energy storage systems, and increasing focus on sustainable power solutions are key factors driving the expansionโฆ
High Voltage Cable Market to Reach $23.4 Billion by 2027 Amid Smart Grid and Ren โฆ
According to a new report published by Allied Market Research, the global high voltage cable market size was valued at $14.6 billion in 2019 and is projected to reach $23.4 billion by 2027, registering a CAGR of 6.0% from 2020 to 2027. The steady expansion of power infrastructure, increasing renewable energy installations, and rising demand for efficient electricity transmission systems are significantly contributing to the growth of the high voltageโฆ
More Releases for PEG
Biopharma PEG Delivers Innovative PEG Solutions for Enhanced Drug Efficacy
Watertown, MA - October 24, 2024 - Biopharma PEG is excited to announce its extensive offerings of polyethylene glycol (PEG) products, including monofunctional, homobifunctional, heterobifunctional, and multi-arm PEGs, tailored for PEGylation in biopharmaceutical applications. With over 40 PEGylated drugs approved globally, the role of PEGylation in drug development is more critical than ever.
PEGylation provides numerous advantages, such as improved solubility, enhanced stability, and increased circulation time in the bloodstream. Byโฆ
Biopharma PEG Expands Multi-Arm PEG Product Line
Biopharma PEG, a leader in PEG derivatives, is excited to announce the expansion of its high-purity Multi-Arm PEG linker product line, catering to the evolving needs of the medical and bioorganic fields. These advanced PEG linkers are available in various functional groups and molecular weights ranging from 1k to 40k, offering unmatched versatility and performance for research and development in cutting-edge medical applications.
"Biopharma PEG is committed to delivering high-purity multi-armโฆ
Biopharma PEG Supplies PEG Products Used For Infectious Disease Vaccines
As of January 1, 2023, global vaccine development includes a total of 966 vaccine candidates, of which 23% (220) are traditional inactivated or attenuated vaccines. Advances in molecular technology have facilitated the development of other platforms, such as recombinant protein vaccines, nucleic acid vaccines, and viral vector vaccines, which have further diversified global vaccine development.
Recombinant protein vaccines accounted for the largest proportion of all pipeline in development, 22% (215), dueโฆ
Biopharma PEG Supplies PEG Products For Click Chemistry Reactions
What is "click chemistry"? "Click Chemistry", this is a literary name given to this kind of reaction by the Nobel Prize winner K.Burry Sharless, when the cards are put together, "click" (click). Simply put, it is to add two structures to two molecules respectively, and these two structures can be specifically combined to synthesize the required chemical molecules. One of the most famous click-chemistry reactions is the Cu-catalyzed azide-alkyne cycloadditionโฆ
Biopharma PEG Develops PEG Linkers for Antibody Drug Conjugates
Antibody-drug conjugate (ADC) is one of the fastest growing fields in tumor therapy, which consists of monoclonal antibody (Antibody), linker (Linker) and active drug (Payload). So far, there are only 15 drugs on the market in the world. However, with the development of some perfect antibody modification techniques, advanced site-specific coupling techniques and powerful small-molecule toxins, ADC drug research has mushroomed and a large number of ADC drugs are inโฆ
Biopharma PEG Provides Multi-arm PEG Derivatives Crosslinked Into Hydrogels
Polyethylene (ethylene glycol) is a hydrophilic polymer that can have a very high water content when cross-linked into a network. Polyethylene glycol (PEG) is a suitable material for biological applications because it does not normally elicit an immune response. Since the 1970s, PEG has been used to modify therapeutic proteins and peptides in order to increase their solubility, reduce their toxicity, and prolong their cyclic half-lives. In the late 1970s,โฆ
